Late effects and survival of children with malignant solid tumours in northern Finland: a single-centre cohort study

Abstract

The global survival rates for childhood cancers are high: approximately 80% of affected children will survive. Nevertheless, the burden of treatment for survivors is also high as three-quarters experience late effects of varying severity following cancer treatment. The aims of this study were to evaluate the treatment-related late effects of patients with childhood solid tumour in northern Finland and to report their survival rates. Our study included 104 patients treated for malignant solid tumours, excluding central nervous system tumours and lymphomas, between 1990 and 2015. Information regarding the type of late effects as well as other clinical data were obtained from the patients’ medical records. Late effects were observed in 65 (63%) patients, and almost half (40%) of the patients displayed more than one late effect. The most common late effect was hearing loss (n = 20). The 5-year survival rate in our study was 75%. Conclusion: Our results highlight the importance of long-term follow-up for childhood cancer survivors. As survivors age and survival rates improve, late effects and their impact on patient health as well as the value of surveillance must be considered. What is Known:• Up to three-quarters of childhood cancer survivors experience treatment-related late effects. What is New:• The 5-year survival rate and the prevalence of late effects amongst childhood solid tumour patients treated in northern Finland are in line with findings from previous studies.

Curcumin nanoparticles combined with 3D printed bionic tumor models for breast cancer treatment

“…Breast cancer is the leading cause of cancer and cancer-related deaths among women worldwide which is a disease of global health importance that can have a tremendous psychosocial impact. With 2.26 million new cases of breast cancer and 2.2 million new cases of lung cancer in 2020, breast cancer officially replaces lung cancer as the number one cancer worldwide (accounting for 11.7% of all new cases) [1,2]. As a result, breast cancer research requires significant investment in treatment and technology development.…”